Headline: BioAge Announces Proposed $75 Mln Public Offering; Expands BGE-102 Development Into Ophthalmology

BioAge Inc. (BIOA) announced a proposed public offering of up to $75 million in shares, with proceeds intended to fund clinical development of its lead candidate BGE-102, now expanding into ophthalmology indications. The move follows positive preclinical data suggesting BGE-102’s potential in treating age-related macular degeneration (AMD). The company plans to use the capital to advance Phase 2 trials for BGE-102 in both neurodegenerative and ocular diseases. Shares of BioAge rose 8.3% in after-hours trading following the announcement. The offering is expected to close on February 15, 2026, subject to regulatory approvals and market conditions.